New Clues Explain Why Immunotherapy Fails in Pancreatic Cancer

Follow Drugslib on

By Carole Tanzer Miller HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

SUNDAY, April 19, 2026 — Immunotherapy has largely failed as a treatment for cancer of the pancreas, and researchers have zeroed in on a key reason.

Pancreatic tumors reprogram immune cells that normally shut down tumor-killing cells, according to a team at Oregon Health & Science University in Portland.

"Pancreatic cancer is incredibly resistant to most therapies," said senior author Katelyn Byrne, an assistant professor at the OHSU School of Medicine.

“Even when we know the immune system is capable of long‑lasting protection, it’s been very difficult to get that response to work in this disease,” she added in a news release.

Immunotherapies like immune checkpoint inhibitors have revolutionized treatment of melanoma and lung cancer. But they haven’t shown the same benefit for pancreatic cancer, the third-leading cause of cancer-related death in the U.S.

The presence inside pancreatic tumors of large numbers of regulatory T cells (Tregs) is a big reason why. Simply put, they overtake immune cells capable of killing tumors.

"If there are a lot of them in a tumor, it’s extremely hard to get an anti-tumor immune response going," Byrne said.

She and her team reported this month in the journal Immunity on mouse tests of an experimental immunotherapy.

Known as agonistic CD40, it works differently from standard checkpoint inhibitors.

Instead of targeting one immune signal, it activates a broader response.

And it didn’t just activate tumor-killing cells, researchers were surprised to find, it converted them into cells that supported anti-tumor activity.

"We didn’t expect this," Byrne said. "Cells that were shutting down the immune reaction suddenly started supporting tumor killing."

The findings help explain why many immunotherapies don’t work in pancreatic cancer and suggest a possible solution.

Treatments may need to attack with a double-whammy — activating the immune system while overcoming the tumor’s own ability to shut it down.

While results of studies in animals often differ in the humans, these discoveries could be meaningful in treating a disease in which most patients stop responding to available treatments over time, researchers said.

Combo strategies could make immunotherapy useful, Byrne said.

The research also points to opportunities to combine immune-based treatments with newer cancer drugs, such as KRAS inhibitors, that directly attack pancreatic cancer cells but still rely on immune support.

"You can imagine hitting the cancer cell with a targeted drug while also reprogramming the immune environment around it," Byrne said. "That combination could be much more effective than either approach alone."

Clinical trials using this combo therapy should be underway in humans within the next several years, she said.

Her lab is now working to better understand the communication between immune cells inside pancreatic tumors and to find out whether the reprogrammed cells offer long-term protection.

Sources

  • Oregon Health & Science University, news release, April 10, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-04-20 01:42

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords